Cargando…
Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials
BACKGROUND: Hyperinflammation and coagulopathy are hallmarks of COVID-19 and synergistically contribute to illness progression. Antiplatelet agents have been proposed as candidate drugs for COVID-19 treatment on the basis of their antithrombotic and anti-inflammatory properties. A systematic review...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490267/ https://www.ncbi.nlm.nih.gov/pubmed/36160149 http://dx.doi.org/10.3389/fmed.2022.965790 |
_version_ | 1784793050172620800 |
---|---|
author | Zong, Xiaolong Wang, Xiao Liu, Yaru Li, Zhenyu Wang, Weiding Wei, Dianjun Chen, Zhuqing |
author_facet | Zong, Xiaolong Wang, Xiao Liu, Yaru Li, Zhenyu Wang, Weiding Wei, Dianjun Chen, Zhuqing |
author_sort | Zong, Xiaolong |
collection | PubMed |
description | BACKGROUND: Hyperinflammation and coagulopathy are hallmarks of COVID-19 and synergistically contribute to illness progression. Antiplatelet agents have been proposed as candidate drugs for COVID-19 treatment on the basis of their antithrombotic and anti-inflammatory properties. A systematic review and meta-analysis that included early observational studies and recent randomized controlled trials (RCTs) was performed to summarize and compare evidence on this issue. METHODS: PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched to identify studies published up to Nov 7, 2021, and the results of registered clinical trials were followed up to Mar 30, 2022. We included RCTs and observational studies assessing the effect of antiplatelet therapy in adult patients with COVID-19. Data on baseline patient characteristics, interventions, controls, and outcomes were extracted by two independent reviewers. The primary outcome was mortality. Data were pooled using a random-effects model. RESULTS: Twenty-seven studies were included, of which 23 observational studies were pooled in a meta-analysis, and the remaining four RCTs (ACTIV-4B, RECOVERY, ACTIV-4a, and REMAP-CAP) were narratively synthesized. Based on 23 observational studies of 87,824 COVID-19 patients, antiplatelet treatment favors a lower risk of mortality [odds ratio (OR) 0.72, 95% confidence interval (CI) 0.61–0.85; I(2) = 87.0%, P < 0.01]. The narrative synthesis of RCTs showed conflicting evidence, which did not support adding antiplatelet therapy to the standard care, regardless of the baseline illness severity and concomitant anticoagulation intensity. CONCLUSION: While the rationale for using antiplatelet treatment in COVID-19 patients is compelling and was supported by the combined result of early observational studies, evidence from RCTs did not confirm this approach. Several factors that could explain this inconsistency were highlighted alongside perspectives on future research directions. |
format | Online Article Text |
id | pubmed-9490267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94902672022-09-22 Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials Zong, Xiaolong Wang, Xiao Liu, Yaru Li, Zhenyu Wang, Weiding Wei, Dianjun Chen, Zhuqing Front Med (Lausanne) Medicine BACKGROUND: Hyperinflammation and coagulopathy are hallmarks of COVID-19 and synergistically contribute to illness progression. Antiplatelet agents have been proposed as candidate drugs for COVID-19 treatment on the basis of their antithrombotic and anti-inflammatory properties. A systematic review and meta-analysis that included early observational studies and recent randomized controlled trials (RCTs) was performed to summarize and compare evidence on this issue. METHODS: PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched to identify studies published up to Nov 7, 2021, and the results of registered clinical trials were followed up to Mar 30, 2022. We included RCTs and observational studies assessing the effect of antiplatelet therapy in adult patients with COVID-19. Data on baseline patient characteristics, interventions, controls, and outcomes were extracted by two independent reviewers. The primary outcome was mortality. Data were pooled using a random-effects model. RESULTS: Twenty-seven studies were included, of which 23 observational studies were pooled in a meta-analysis, and the remaining four RCTs (ACTIV-4B, RECOVERY, ACTIV-4a, and REMAP-CAP) were narratively synthesized. Based on 23 observational studies of 87,824 COVID-19 patients, antiplatelet treatment favors a lower risk of mortality [odds ratio (OR) 0.72, 95% confidence interval (CI) 0.61–0.85; I(2) = 87.0%, P < 0.01]. The narrative synthesis of RCTs showed conflicting evidence, which did not support adding antiplatelet therapy to the standard care, regardless of the baseline illness severity and concomitant anticoagulation intensity. CONCLUSION: While the rationale for using antiplatelet treatment in COVID-19 patients is compelling and was supported by the combined result of early observational studies, evidence from RCTs did not confirm this approach. Several factors that could explain this inconsistency were highlighted alongside perspectives on future research directions. Frontiers Media S.A. 2022-09-07 /pmc/articles/PMC9490267/ /pubmed/36160149 http://dx.doi.org/10.3389/fmed.2022.965790 Text en Copyright © 2022 Zong, Wang, Liu, Li, Wang, Wei and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Zong, Xiaolong Wang, Xiao Liu, Yaru Li, Zhenyu Wang, Weiding Wei, Dianjun Chen, Zhuqing Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials |
title | Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials |
title_full | Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials |
title_fullStr | Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials |
title_full_unstemmed | Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials |
title_short | Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials |
title_sort | antiplatelet therapy for patients with covid-19: systematic review and meta-analysis of observational studies and randomized controlled trials |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490267/ https://www.ncbi.nlm.nih.gov/pubmed/36160149 http://dx.doi.org/10.3389/fmed.2022.965790 |
work_keys_str_mv | AT zongxiaolong antiplatelettherapyforpatientswithcovid19systematicreviewandmetaanalysisofobservationalstudiesandrandomizedcontrolledtrials AT wangxiao antiplatelettherapyforpatientswithcovid19systematicreviewandmetaanalysisofobservationalstudiesandrandomizedcontrolledtrials AT liuyaru antiplatelettherapyforpatientswithcovid19systematicreviewandmetaanalysisofobservationalstudiesandrandomizedcontrolledtrials AT lizhenyu antiplatelettherapyforpatientswithcovid19systematicreviewandmetaanalysisofobservationalstudiesandrandomizedcontrolledtrials AT wangweiding antiplatelettherapyforpatientswithcovid19systematicreviewandmetaanalysisofobservationalstudiesandrandomizedcontrolledtrials AT weidianjun antiplatelettherapyforpatientswithcovid19systematicreviewandmetaanalysisofobservationalstudiesandrandomizedcontrolledtrials AT chenzhuqing antiplatelettherapyforpatientswithcovid19systematicreviewandmetaanalysisofobservationalstudiesandrandomizedcontrolledtrials |